BMS REPORTS PHASE II ABATACEPT DATA

A A

Patients with rheumatoid arthritis who have not responded adequately to methotrexate monotherapy appear to have improved quality of life, sleep, and fatigue when they are treated with Bristol-Myers Squibb's (BMS) abatacept, according to new study data.

A one-year, double-blind, placebo-controlled Phase II trial assessed fixed-dose abatacept at a dose approximating 10 mg/kg in combination with methotrexate or placebo. In the trial, patients received abatacept 10 mg/kg with methotrexate or with placebo for up to one year, followed by abatacept at a dose approximating 10 mg/kg for the remainder of the study.